Navigation Links
Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene

ANNAPOLIS, Md., Dec. 24, 2015 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that the Delaware Supreme Court affirmed the Delaware Court of Chancery's decision to award PharmAthene lump sum expectation damages for the value of PharmAthene's lost profits for SIGA's smallpox antiviral, Tecovirimat. The Delaware Court of Chancery awarded PharmAthene $113 million in expectation damages plus interest and other costs, which if calculated based on the original decision (and including post-judgment interest) would provide for an estimated total of approximately $205 million. PharmAthene's ability to collect a monetary judgment, including post-petition interest, from SIGA remains subject to further proceedings in the Federal Bankruptcy Court. SIGA has filed a reorganization plan with the Court that provides for among other things, the process by which PharmAthene's judgment may be satisfied, but that plan has not been approved by the Bankruptcy Court and remains subject to change, withdrawal or rejection by the Court. A copy of the Delaware Supreme Court decision is available at:

A copy of the SIGA reorganization plan filed with the bankruptcy court is available at:

About PharmAthene
PharmAthene is a biodefense company engaged in the development of next generation medical countermeasures against biological and chemical threats. The Company's development portfolio includes two next generation Anthrax vaccines that are intended to improve protection while having favorable dosage and storage requirements compared other Anthrax vaccines.

On January 15, 2015, the Delaware Court of Chancery issued its Final Order and Judgment in PharmAthene's litigation against SIGA. The Court of Chancery awarded to PharmAthene lump sum expectation damages for the value of PharmAthene's lost profits for SIGA's smallpox antiviral, Tecovirimat, also known as ST-246® (formerly referred to as "Arestvyr™" and referred to by SIGA in its recent SEC filings as "Tecovirimat"). In addition, the Court of Chancery ordered SIGA to pay pre-judgment interest and varying percentages of PharmAthene's reasonable attorneys' and expert witness fees.

Forward-Looking Statement Disclaimer
Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risks associated with the judgment relating to Tecovirimat, also known as ST-246® (formerly referred to as "Arestvyr™" and referred to by SIGA in its recent SEC filings as "Tecovirimat") (including the risk that we will not be able to collect any amounts related thereto); and other risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission.

The final award may be subject to further proceedings before the Delaware Courts.  There can be no assurances if and when PharmAthene will receive any payments from SIGA as a result of the decision. SIGA has stated publicly that it does not currently have cash sufficient to satisfy the award. It is also uncertain whether SIGA will have such cash in the future. PharmAthene's ability to collect the Judgment depends upon a number of factors, including SIGA's financial and operational success, which is subject to a number of significant risks and uncertainties (certain of which are outlined in SIGA's filings with the SEC), as to which we have limited knowledge and which we have no ability to control, mitigate or fully evaluate. Because SIGA has filed for protection under the federal bankruptcy laws, PharmAthene is automatically stayed from taking any enforcement action in the Delaware Court of Chancery. By agreement of the parties, and with the approval of the Bankruptcy Court, the automatic stay has been lifted for the sole purpose of allowing the Delaware Court of Chancery to enter a money judgment and to allow the parties to exercise their appellate rights. On December 15, 2015, SIGA filed with the U.S. Bankruptcy Court for the Southern District of New York a reorganization plan that sets out the terms and conditions under which SIGA will seek to exit from bankruptcy. The plan filed was negotiated between SIGA and the Statutory Creditor's Committee of which PharmAthene is a member. The plan is subject to approval by the bankruptcy court, on a timeline to be determined. No assurance can be given that the U.S. Bankruptcy Court for the Southern District of New York will approve the reorganization plan or that as a result thereof, we will receive any award of money damages from SIGA or otherwise receive any benefit therefrom.

Copies of PharmAthene's public disclosure filings are available on our website under the investor relations tab at

SOURCE PharmAthene, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Positron Announces Reverse Stock Split and Registration as a Delaware Corporation
2. Delaware Court of Chancery Orders SIGA To Pay PharmAthene Lump Sum Expectation Damages
3. TV Mesh Lawsuit Funding Firm, Fair Rate Funding, Reports Delaware Woman Awarded $100 Million Against Boston Scientific in Pelvic Mesh Verdict.
4. CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware
5. Delaware Prescription Drug Action Committee and Delaware Pharmacists Society Support New Home Drug Disposal Pilot Providing Free Deterra Drug Deactivation Products
6. Supreme Court Ruling Today Allows DNATraits to Offer Low Cost BRCA Breast and Ovarian Cancer Gene Testing in U.S.
7. U.S. Supreme Court Reverses U.S. Court of Appeals Decision in FTC v. Actavis
8. Supreme Court Ruling on Rx Industrys Pay-to-Delay-Generics Good News for NY Consumers
9. Academy of Managed Care Pharmacy Comments on U.S. Supreme Courts Ruling in King vs. Burwell
10. Statement on Supreme Court of Canada Decision in R. v. Smith
11. Elbit Imaging Announces the Court Decision with Respect to Filing of Plan of Arrangement with the Israeli Court
Post Your Comments:
(Date:8/21/2019)... Colo. (PRWEB) , ... August 21, 2019 , ... ... improving patron experience by lowering pool chemical use with Clear Comfort’s Advanced Oxidation ... is able to save significant chemical expense dollars, simplify its water care protocol ...
(Date:8/19/2019)... ... August 19, 2019 , ... ... their 2nd Annual National Sports Summit, August 25-26 at the Hyatt Place in ... leaders from all major professional sports programs to discuss progress made over the ...
(Date:8/19/2019)... ... August 19, 2019 , ... ... today announced the findings of research validating the clinical impact of MedAware’s machine ... published 7 August 2019 in the Journal of American Medical Informatics Association ...
Breaking Medicine Technology:
(Date:8/16/2019)... ... August 16, 2019 , ... Tim ... throughout the Mid-Atlantic and North East at the 2019 Safety Academy sponsored through ... build on existing construction safety concepts and define not only a safety program ...
(Date:8/15/2019)... ... August 15, 2019 , ... ... annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private ... the American economy’s most dynamic segment—its independent small businesses. Microsoft, Dell, Domino’s Pizza, ...
(Date:8/15/2019)... ... August 15, 2019 , ... With many students either starting college for the first time, ... demographic. According to the CDC , “there are about 20 million new cases of ... between the ages of 15 and 24. Young people are at greater risk of getting ...
(Date:8/15/2019)... ... August 15, 2019 , ... Heritage Woods of Rockford Administrator Jaclyn ... Living (NCAL). , This award is part of the NCAL Awards Program, which recognizes ... “The common element among this year’s recipients is that they all go out of ...
(Date:8/14/2019)... Colo. (PRWEB) , ... August 14, 2019 , ... Inc. ... #2008 on its annual Inc. 5000 list, the most prestigious ranking of the nation’s ... #41 among Colorado based companies and #153 in the Health sector. The list represents ...
Breaking Medicine News(10 mins):